Layn(002166) 华鑫证券·2024-07-10 01:00Investment Rating - The report maintains a "Buy" investment rating for the company [24][30]. Core Views - The company is benefiting from the growing demand in the plant extract market and its improved operational capabilities, leading to significant revenue growth. The expected net profit for the first half of 2024 is projected to be between 54-65 million, representing a year-on-year increase of 50%-80% [25]. - The company is expanding into synthetic biology and enhancing its product offerings to meet customized client needs, with plans to complete the construction of a stevia extraction plant and synthetic biology workshop in 2024 [30]. - The company aims to leverage opportunities in emerging markets like ASEAN to solidify its market position and drive sustainable growth [30]. Financial Summary - Revenue projections for 2023A, 2024E, 2025E, and 2026E are 1,494 million, 1,793 million, 2,115 million, and 2,453 million respectively, with growth rates of 6.7%, 20.0%, 18.0%, and 16.0% [16]. - The expected net profit for 2023A, 2024E, 2025E, and 2026E is 83 million, 180 million, 246 million, and 347 million respectively, with growth rates of -53.8%, 117.9%, 37.0%, and 40.7% [16]. - The projected EPS for 2024, 2025, and 2026 is 0.24, 0.33, and 0.47 respectively, with corresponding PE ratios of 27, 20, and 14 [30].